FDA to Co-Sponsor June 2012 CGMP conference in Baltimore.
Share:
Press Release Summary:
As announced by ISPE, FDA will co-sponsor "Redefining the 'C' in 'CGMP'" Conference in Baltimore, MD, USA from June 4-5, 2012. New format will features number of audience-participation and interactive sessions. Also, Hot Topic Discussion Forum between attendees and regulators will offer interactive insight on critical industry issues, concerns, and collaboration. Mixed panel of FDA and industry leaders will also answer pressing industry questions during moderated "Meet the Press" session.
Original Press Release:
ISPE Announces FDA to Co-Sponsor June CGMP Conference in Baltimore
(TAMPA, FLORIDA, USA) - ISPE announced today the Food and Drug Administration (FDA) will co-sponsor the upcoming "Redefining the 'C' in 'CGMP'" Conference in Baltimore, Md. USA on 4 - 5 June 2012. The conference is the first joint ISPE-FDA conference focused on CGMP issues.
The conference will feature a new format with a number of audience-participation and interactive sessions. A Hot Topic Discussion Forum between attendees and regulators will feature discussion on critical industry issues, concerns and collaboration. A mixed panel of FDA and industry leaders will also answer the industry's most pressing questions during a moderated "Meet the Press" session. Topical plenary and education sessions will be featured throughout the two-day event.
"This first annual co-sponsored conference reflects ISPE's commitment to engaging its Members, companies and global regulatory agencies in dialog around critical problem-solving and learning," said ISPE's president and CEO Nancy Berg. "As the independent pharmaceutical manufacturing association, ISPE is dedicated to strengthening industry through relevant technical education, training and networking. This new conference hits the mark, assembling the entire supply chain to discuss industry's commitment to identifying and adopting quality and manufacturing techniques that continue to deliver a safe, consistent and available drug supply."
"FDA is very excited to be working on this joint conference," said Steven Lynn, Acting Director, FDA/CDER/Office of Compliance/ Office of Manufacturing and Product Quality (OMPQ). "Our goal is to make this a highly collaborative Agency and Industry conference, where we can come together to discuss the current and future state of CGMPs in the quest to ensure high-quality/fit-for-use drugs are continually available to the community that we serve."
More information on the Redefining the "C" in "CGMP" Conference is available at www.ISPE.org/2012CGMPCompliance.
About ISPE
ISPE, the International Society for Pharmaceutical Engineering, is a not-for-profit Society of 22,000 pharmaceutical professionals in 90 countries who use expert knowledge to create high-quality, cost-effective GMP solutions. Founded in 1980, ISPE offers online learning opportunities for a global audience and has its worldwide headquarters in Tampa, Fla., USA, as well as offices in Brussels, Belgium, Singapore and Shanghai, China. Visit www.ISPE.org for additional Society news and information.
